A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases. After receiving 180 µCi (1.35 µCi/kg) of 223Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat 223Ra chloride administrations. 223Ra chloride is the first Food and Drug Administration–approved unsealed α-emitting radiopharmaceutical.
From the University of Southern California, Los Angeles, CA.
Received for publication June 28, 2013; revision accepted June 28, 2013.
Conflicts of interest and sources of funding: none declared.
Reprints: Patrick M. Colletti, MD, University of Southern California, LAC+USC Medical Center, 1200 N State St, Los Angeles, CA 90033. E-mail: email@example.com.